Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection
Published version of a preprint
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Dasatinib is a multitargeted kinase inhibitor that was recently approved for the treatment of chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. It is also in clinical trials for treating patients with solid tumors. The identification of molecular markers predictive of response to dasatinib could assist in clinical development by selecting patients most likely to derive clinical benefit. Using baseline gene expression profiling of a panel of 23 breast cancer cell lines, we identified genomic signatures highly correlated with in vitro sensitivity to dasatinib. The ability of these signatures to predict dasatinib sensitivity was further confirmed and validated in independent test cell lines. A six-gene model was used to correctly predict dasatinib sensitivity in 11 out of 12 (92%) additional breast and 19 out of 23 (83%) lung cancer cell lines. Quantitative real-time PCR and immunohistochemical assays further confirmed the differential expression pattern of selected markers. Finally, these gene signatures were observed in a subset of primary breast, lung, and ovarian tumors suggesting potential utility in patient selection. The subset of breast cancer patients expressing the dasatinib-sensitive signature includes a distinct clinical and molecular subgroup: the so-called “triple negative” (i.e., estrogen receptor–negative, progesterone receptor–negative, and HER2-negative) or “basal” breast cancer subtype. This patient population has a poor prognosis and currently has few effective treatment options. Our results implicate that dasatinib may represent a valuable treatment option in this difficult-to-treat population. To test this hypothesis, clinical studies are now under way to determine the activity of dasatinib in these patients. [Cancer Res 2007;67(5):2226–38]
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, we generated a 5-gene dasatinib sensitivity (Dasa-S) signature score from the 5 up-regulated genes of a reported 6-gene dasatinib sensitivity signature (5 UP genes EPHA2, CAV1, CAV2, ANXA1, PTRF and 1 DOWN gene IGFBP2) that was developed in breast cell lines and validated in lung cell lines to predict sensitivity to dasatinib in solid tumors including breast, lung and ovary [28].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [28]
In the citing paper
“All of the five up-regulated genes are targets of dasatinib, substrates for SRC family kinases, or part of signaling pathways downstream of SRC family kinases [28].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [28]
Citations
Cites
1 retracted
Duxbury, M. S., Ito, H., Ashley, S. W., & Whang, E. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402051200 · Cited by 55
RetractedMolecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · cited 1×
“More recently, gene expression profiling studies have shown the advantages of genomic ‘‘signatures’’ or marker sets generated by microarray analysis in classifying tumors (5–7), predicting clinical outcome (8, 9), and chemotherapeutic response (10–13).”
BackgroundPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Giancotti, F. G., & Ruoslahti, E. (1999) · Science · doi:10.1126/science.285.5430.1028 · Cited by 3,869
CELLULAR FUNCTIONS REGULATED BY SRC FAMILY KINASES
Thomas, S. M., & Brugge, J. S. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.513 · Cited by 2,498
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Research works printed but not linked: 1
- Finn RS, Dering J, Wilson CA, et al. Biologic effects and identification of predictive markers of response to Dasatinib (BMS-354825), novel, oral, multi-targeted kinase inhibitor in human breast cancer cell lines in vitro. Clin Cancer Res 2005; 11: 9022s.
Cited by
Eph receptors and ephrins in cancer: bidirectional signalling and beyond
Pasquale, E. B. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2806 · Cited by 1,226
“Furthermore, EPHA2 seems to be preferentially expressed in malignant breast and prostate cancers with a basal phenotype”
BackgroundBasal-Like Breast Cancer: A Critical Review
Rakha, E. A., Reis-Filho, J. S., & Ellis, I. O. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1748 · Cited by 1,164
Triple negative tumours: a critical review
Reis‐Filho, J. S., & Tutt, A. N. J. (2008) · Histopathology · doi:10.1111/j.1365-2559.2007.02889.x · Cited by 884
“Furthermore, patients who responded to this tyrosine kinase inhibitor had cancers preferentially lacking ER, PR and HER2 and expressing CK5 and CK17.(77) Although the actual targets of dasatinib in triplenegative breast cancer are yet to be validated, a sixgene predictor including EPHA2, CAV1, CAV2, ANXA1 PTRF and IGF…”
BackgroundInfluentialChavez, K. J., Garimella, S. V., & Lipkowitz, S. (2011) · Breast Disease · doi:10.3233/bd-2010-0307 · Cited by 762
“Further study will be necessary to determine if the expression signatures or other molecular markers developed in preclinical studies using the cell lines will allow the identification of a subset of patients in whom dasatinib is efficacious [68, 69].”
BackgroundTriple-negative breast cancer—current status and future directions
Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., & Harbeck, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp492 · Cited by 687
“In vitro evidence supports the use of this small molecule particularly in subgroup of BLBC in which several tyrosine kinase receptors such as stem-cell factor receptor (c-kit) are overexpressed and/or mutated [155, 156].”
Background
Metadata
- Authors
- Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., & Clark, E.
- Affiliations
- 1Clinical Discovery and Departments of
- Bristol-Myers Squibb (United States) (US)
- Venue
- Cancer Research
- Published
- 2007-03-01
- Volume
- 67
- Issue
- 5
- Pages
- 2226-2238
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2044858733
- Cited by
- 344
- References
- 48
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 6 · 2023: 20 · 2022: 12 · 2021: 17 · 2020: 7 · 2019: 4 · 2018: 7 · 2017: 10 · 2016: 12 · 2015: 13 · 2014: 24 · 2013: 18 · 2012: 22
- FWCI
- 14.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- dasatinib, molecular markers, drug response prediction, kinase inhibitors, breast cancer cell lines, lung cancer cell lines, ovarian cancer, gene expression signatures, triple-negative breast cancer, basal-like breast cancer, patient selection, multikinase inhibitor
- MeSH terms
- Dasatinib, Antineoplastic Agents, Breast Neoplasms, Humans, Models, Genetic, Prognosis, Pyrimidines, Thiazoles, Biomarkers, Tumor, Patient Selection, Drug Resistance, Neoplasm, Gene Expression Profiling, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-3633
- The paper
- Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., & Clark, E. (2007). Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-3633
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.